Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

4/15/25 12:40:46 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GSK

Date	Price Target	Rating	Analyst
6/3/2025		Buy → Hold	Berenberg
4/15/2025	$35.25	Neutral	Exane BNP Paribas
2/12/2025		Equal-Weight	Morgan Stanley
11/15/2024		Buy → Hold	Deutsche Bank
11/12/2024	$53.00 → $39.50	Buy → Hold	Jefferies
10/31/2024		Buy → Neutral	Guggenheim
7/8/2024		Buy → Neutral	UBS
5/30/2024	$47.00	Neutral	Goldman